Renal involvement in chronic lymphocytic leukemia

被引:32
作者
Wanchoo, Rimda [1 ]
Ramirez, Carolina Bernabe [2 ]
Barrientos, Jacqueline [2 ,3 ]
Jhaveri, Kenar D. [1 ]
机构
[1] Zucker Sch Med Hofstra Northwell, Div Kidney Dis & Hypertens, Great Neck, NY 11021 USA
[2] Zucker Sch Med Hofstra Northwell, Div Hematol & Oncol, Lake Success, NY USA
[3] CLL Res & Treatment Program, Lake Success, NY USA
关键词
AKI; CLL; infiltration; leukemia; onconephrology; paraproteinemia; venetoclax; TUMOR LYSIS SYNDROME; B-CELL LYMPHOCYTOSIS; LIGHT-CHAIN; OPEN-LABEL; LYMPHOPROLIFERATIVE DISORDERS; MONOCLONAL GAMMOPATHY; PSEUDOHYPERKALEMIA; HYPERCALCEMIA; RITUXIMAB; PATIENT;
D O I
10.1093/ckj/sfy026
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in the USA and Western Europe. Kidney disease can present in patients with CLL as a manifestation of the disease process such as acute kidney injury with infiltration or with a paraneoplastic glomerular disease or as a manifestation of extra renal obstruction and tumor lysis syndrome. In the current era of novel targeted therapies, kidney disease can also present as a complication of treatment. Tumor lysis syndrome associated with novel agents such as the B-cell lymphoma 2 inhibitor venetoclax and the monoclonal antibody obinutuzumab are important nephrotoxicities associated with these agents. Here we review the various forms of kidney diseases associated with CLL and its therapies.
引用
收藏
页码:670 / 680
页数:11
相关论文
共 50 条
  • [21] A Patient with Chronic Lymphocytic Leukemia with Pancreatic Involvement
    Essrani, Rajesh
    Sullivan, Matthew J.
    Shah, Hiral
    CASE REPORTS IN HEMATOLOGY, 2019, 2019
  • [22] Chronic lymphocytic leukemia in China
    Gale, Robert Peter
    CHINESE MEDICAL JOURNAL, 2022, 135 (08) : 883 - 886
  • [23] Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia
    Marini, Bernard L.
    Samanas, Lisa
    Perissinotti, Anthony J.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (07) : 502 - 517
  • [24] Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
    Shustik, C.
    Bence-Bruckler, I.
    Delage, R.
    Owen, C. J.
    Toze, C. L.
    Coutre, S.
    ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1185 - 1196
  • [25] What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
    Cheson, Bruce D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (11) : 723 - 727
  • [26] The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia
    Al-Sawaf, Othman
    Hallek, Michael
    Fischer, Kirsten
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 97 - 103
  • [27] Changing landscape of frontline therapy in chronic lymphocytic leukemia
    Bhat, Seema A.
    Woyach, Jennifer A.
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 525 - 535
  • [28] Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective
    Owen, Carolyn
    Assouline, Sarit
    Kuruvilla, John
    Uchida, Cassandra
    Bellingham, Catherine
    Sehn, Laurie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11) : 627 - 634
  • [29] Chronic Diarrhea Caused by Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma With Colorectal Involvement
    Xie, Chencheng
    Aloreidi, Khalil
    Gilbert, Jorge
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (03) : XXXIII - +
  • [30] Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia
    Strati, Paolo
    Uhm, Joon H.
    Kaufmann, Timothy J.
    Nabhan, Chadi
    Parikh, Sameer A.
    Hanson, Curtis A.
    Chaffee, Kari G.
    Call, Timothy G.
    Shanafelt, Tait D.
    HAEMATOLOGICA, 2016, 101 (04) : 458 - 465